ABT-263, also known as Navitoclax, is a small molecule drug developed for the treatment of various types of cancer. It belongs to the class of drugs known as BH3 mimetics, which are designed to target and inhibit proteins that promote cancer cell survival.
Chemical Name: The chemical name of ABT-263 Navitoclax is 4-(4-{2-[4-(4-chloro-3-trifluoromethylphenyl) piperazin-1-yl]ethyl}-1-piperidinyl)-N-[(4-fluorophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide.
Molecular Formula: The molecular formula of ABT-263 Navitoclax is C47H55ClF6N6O5S.
Formula Weight: The molecular weight of ABT-263 Navitoclax is 974.53 g/mol.
CAS No: The CAS number of ABT-263 Navitoclax is 923564-51-6.
Top Ten Keywords from Google and Synonyms:
Synonyms: ABT-263 Navitoclax is also known by its brand name, "Navitoclax." Other synonyms include ABT-263 and an inhibitor of B-cell lymphoma 2 (BCL-2).
Health Benefits of ABT-263 Navitoclax: ABT-263 Navitoclax is still under development; hence, there are no established health benefits at present. However, preclinical studies have shown that it has significant potential in inhibiting tumor growth and proliferation in various cancer types, including chronic lymphocytic leukemia, non-small cell lung cancer, and ovarian cancer.
Potential Effects: Preclinical studies have demonstrated that ABT-263 Navitoclax acts as a BH3 mimetic, selectively targeting and inhibiting anti-apoptotic proteins, such as BCL-2, BCL-XL, and BCL-W. These proteins play a critical role in promoting cancer cell survival, and by inhibiting them, ABT-263 Navitoclax can induce cancer cell death and hinder tumor growth and progression. Additionally, it has shown promising results in combination with other targeted therapies, such as inhibitors of PI3K, in preclinical models of solid tumors.
Product Mechanism: ABT-263 Navitoclax is a selective inhibitor of BCL-2, BCL-XL, and BCL-W, three anti-apoptotic proteins involved in regulating cell survival and death. By binding to these proteins, ABT-263 Navitoclax mimics the pro-apoptotic protein BAD, which triggers the release of cytochrome c and initiates apoptosis, or programmed cell death, in cancer cells.
Safety: ABT-263 Navitoclax has been shown to have manageable toxicities in early-phase clinical trials. However, it is essential to carry out rigorous safety assessments before it becomes available for widespread use.
Side Effects: Common side effects reported in early-phase clinical trials include:
Dosing Information: ABT-263 Navitoclax is currently being evaluated in Phase I/II clinical trials to determine the optimal dose and schedule for administration. The recommended dose and dosing regimen will be determined based on the outcome of these trials.
Conclusion: ABT-263 Navitoclax is a promising new drug candidate for the treatment of cancer. By selectively targeting and inhibiting anti-apoptotic proteins, it can induce cancer cell death and hinder tumor growth and progression. Early-phase clinical trials have reported manageable toxicities, and ongoing clinical trials hope to determine its safety and efficacy further. If proven effective, ABT-263 Navitoclax could offer a new option for patients with various types of cancer associated with overexpression of BCL-2 family proteins. However, more extensive clinical trials are needed to establish its safety profile and determine the most effective dosing regimen.
